Percutaneous approach to detect cytokines in inflammatory skin diseases
- Conditions
- Inflammatory skin disease
- Registration Number
- JPRN-jRCTs062180083
- Lead Sponsor
- Koji Sayama
- Brief Summary
It could be possible to evaluate the skin damage without skin biopsy by analyzing lesional and non-lesional IFN-gamma levels. However, more cases are required to confirm this results. IFN-gamma or TNF-alpha could be easily detectable in cases with severe skin damage.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 32
Inflammatory skin diseases presenting erythematous plaque with slight scaling.
Such as bullous pemphigoid, prurigo chronica multiformis, erythema nodosum, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis, toxicoderma.
1. History of atopic dermatitis
2. Subjects with systemic infectious diseases
3. Defined history of allergic contact dermatitis from adhesive tapes.
4. Other judged as being inappropriate for the study by the investigators.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To investigate if there is correlation between symptoms of each inflammatory skin diseases and the amounts of cytokines detected percutaneously with skin blotting.
- Secondary Outcome Measures
Name Time Method Evaluation of skin blotting for the early diagnosis of severe erythema multiforme such as Stevens-Johnson syndrome, toxic epidermal necrolysis.